Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MeRmaiD-1: Adjuvant durvalumab plus platinum-based chemotherapy in completely resected stage II–III NSCLC
2020-000556-35Phase 3Unknown
- Sponsor
- AstraZeneca
- Start
- Apr 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Durvalumab + platinum-based chemotherapy with Placebo + platinum-based chemotherapy (2 arms). Primary endpoint: Disease-free survival in MRD+ analysis set. Status: unknown.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-000556-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000556-35.